Patrick Rossignol

List of Publications by Year
in descending order

68 papers	1,578 citations	361413 20 h-index	315739 38 g-index
71 all docs	71 docs citations	71 times ranked	2486 citing authors

#	Article	IF	Citations
1	Heart failure drug treatment. Lancet, The, 2019, 393, 1034-1044.	13.7	233
2	Integrative Assessment of Congestion inÂHeart Failure Throughout the PatientÂJourney. JACC: Heart Failure, 2018, 6, 273-285.	4.1	152
3	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the <scp>GISSIâ€HF</scp> and Valâ€<scp>HeFT</scp> trials. European Journal of Heart Failure, 2015, 17, 424-433.	7.1	104
4	Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. Pharmacological Research, 2016, 113, 585-591.	7.1	91
5	Unravelling the interplay between hyperkalaemia, reninâ€“angiotensinâ€“aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESCâ€HFAâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	7.1	83
6	Management of hyperkalemia in the acutely ill patient. Annals of Intensive Care, 2019, 9, 32.	4.6	74
7	Intimaâ€“Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Populationâ€Based Cohort (STANISLAS Cohort Study). Journal of the American Heart Association, 2016, 5, .	3.7	62
8	Prognostic value of pulmonary congestion assessed by lung ultrasound imaging during heart failure hospitalisation: A two-centre cohort study. Scientific Reports, 2016, 6, 39426.	3.3	51
9	Renal function estimation and Cockcroftâ€“Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€˜OMicsâ€™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181.	5.5	48
10	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2015, 115, 790-796.	1.6	37
11	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 2017, 19, 792-799.	7.1	34
12	Diagnostic and prognostic value of plasma volume status at emergency department admission in dyspneic patients: results from the PARADISE cohort. Clinical Research in Cardiology, 2019, 108, 563-573.	3.3	34
13	Cohort Profile: Rationale and design of the fourth visit of the STANISLAS cohort: a familial longitudinal population-based cohort from the Nancy region of France. International Journal of Epidemiology, 2018, 47, 395-395j.	1.9	33
14	Estimated plasma volume status in heart failure: clinical implications and future directions. Clinical Research in Cardiology, 2021, 110, 1159-1172.	3.3	30
15	Hyperkalaemia prevalence, recurrence and management in chronic haemodialysis: a prospective multicentre French regional registry 2-year survey. Nephrology Dialysis Transplantation, 2017, 32, 2112-2118.	0.7	29
16	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. Clinical Research in Cardiology, 2018, 107, 214-221.	3.3	28
17	Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (<scp>AMBER</scp>): results in the preâ€specified subgroup with heart failure. European Journal of Heart Failure, 2020, 22, 1462-1471.	7.1	27
18	Potassium lowering agents: Recommendations for physician and patient education, treatment reappraisal, and serial monitoring of potassium in patients with chronic hyperkalemia. Pharmacological Research, 2017, 118, 2-4.	7.1	26

#	Article	IF	Citations
19	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
20	Association between mean systolic and diastolic blood pressure throughout the followâ€up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the Highâ€Risk Myocardial Infarction Database Initiative. European Journal of Heart Failure, 2018, 20, 323-331.	7.1	23
21	The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney International, 2019, 95, 747-749.	5.2	22
22	Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. International Journal of Cardiology, 2019, 289, 91-98.	1.7	21
23	Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology. Archives of Cardiovascular Diseases, 2020, 113, 660-670.	1.6	21
24	Prognostic impact of plasma volume estimated from hemoglobin and hematocrit in heart failure with preserved ejection fraction. Clinical Research in Cardiology, 2020, 109, 1392-1401.	3.3	21
25	Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: Lessons from randomized controlled trials and registries. International Journal of Cardiology, 2014, 177, 731-733.	1.7	19
26	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. European Journal of Heart Failure, 2020, 22, 1402-1411.	7.1	19
27	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. Clinical Research in Cardiology, 2019, 108, 1215-1225.	3.3	17
28	Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up. American Journal of Hypertension, 2020, 33, 869-878.	2.0	16
29	The value of spot urinary creatinine as a marker of muscle wasting in patients with newâ€onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 555-567.	7.3	15
30	Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study. International Journal of Cardiology, 2020, 299, 192-198.	1.7	14
31	The association between serum potassium and mortality in patients with hypertension: â€˜a wake-up callâ€™. European Heart Journal, 2017, 38, ehw209.	2.2	13
32	Roadmap for cardiovascular prevention trials in chronic kidney disease. Lancet, The, 2016, 388, 1964-1966.	13.7	13
33	Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program. Drugs - Real World Outcomes, 2021, 8, 315-323.	1.6	13
34	A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology. European Heart Journal Supplements, 2019, 21, A48-A54.	0.1	12
35	Renal function, electrolytes, and congestion monitoring in heart failure. European Heart Journal Supplements, 2019, 21, M25-M31.	0.1	11
36	Hyponatraemia, hyperglycaemia and worsening renal function at first blood sample on emergency department admission as predictors of in-hospital death in patients with dyspnoea with suspected acute heart failure: retrospective observational analysis of the PARADISE cohort. BMJ Open, 2018, 8, e019557.	1.9	10

#	Article	IF	Citations
37	Diagnostic performance of congestion score index evaluated from chest radiography for acute heart failure in the emergency department: A retrospective analysis from the PARADISE cohort. PLoS Medicine, 2020, 17, e1003419.	8.4	10
38	Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARICâ€“WHO clinical characterisation protocol. PLoS Medicine, 2022, 19, e1003969.	8.4	10
39	Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure postâ€discharge. ESC Heart Failure, 2020, 7, 1257-1263.	3.1	9
40	Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a populationâ€based study. European Journal of Heart Failure, 2018, 20, 1066-1068.	7.1	8
41	Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort. Clinical Cardiology, 2021, 44, 1516-1525.	1.8	7
42	Hypokalemia is frequent and has prognostic implications in stable patients attending the emergency department. PLoS ONE, 2020, 15, e0236934.	2.5	6
43	Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHESUS trial. Clinical Research in Cardiology, 2022, 111, 380-392.	3.3	6
44	Fatty acid desaturase genetic variations and dietary omega-3 fatty acid intake associate with arterial stiffness. European Heart Journal Open, 2022, 2, .	2.3	6
45	A Combination of Chest Radiography and Estimated Plasma Volume May Predict In-Hospital Mortality in Acute Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 752915.	2.4	5
46	Left-to-right atrial shunting: new hope for heart failure?. Lancet, The, 2016, 387, 1253-1255.	13.7	4
47	Fibrosis mechanistic phenotyping and antifibrotic response determination with biomarkers in heart failure: one single biomarker may not fit all settings. European Journal of Heart Failure, 2018, 20, 1300-1302.	7.1	4
48	Echocardiographic diastolic function evolution in patients with an anterior <scp>Q</scp>â€wave myocardial infarction: insights from the <scp>REVE</scp>â€2 study. ESC Heart Failure, 2019, 6, 70-79.	3.1	4
49	Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners. ESC Heart Failure, 2020, 7, 2042-2050.	3.1	4
50	HeartÂFailure and Chronic Kidney Disease Patients. Journal of the American College of Cardiology, 2021, 78, 344-347.	2.8	4
51	Balancing Benefits and Risks of Spironolactone in HFpEF and ChronicÂKidney Disease Patients. JACC: Heart Failure, 2019, 7, 33-35.	4.1	3
52	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. Clinical Research in Cardiology, 2021, 110, 1308-1320.	3.3	3
53	Reply. JACC: Heart Failure, 2018, 6, 442-443.	4.1	1
54	Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20â€Year Followâ€Up. Journal of the American Heart Association, 2022, 11, e023301.	3.7	1

#	Article	IF	Citations
55	Extracting Meaning of Tubular Injury Molecules: Implications for Cardiorenal Health. American Journal of Nephrology, 2019, 49, 343-345.	3.1	0
56	Hypoâ€•and hyperkalaemia in heart failure. Navigating between Scylla and Charybdis. European Journal of Heart Failure, 2020, 22, 1399-1401.	7.1	0
57	Should reninâ€“angiotensinâ€“aldosterone system inhibition enablement be a therapeutic target in CKD patients?. Nephrology Dialysis Transplantation, 2021, 36, 1771-1772.	0.7	0
58	A Step Forward Toward a New Treatment Paradigm in the Cardiorenal Continuum. JACC: Heart Failure, 2021, 9, 821-823.	4.1	0
59	Is it time to shift our focus from treatment to prevention of heart failure with a mineralocorticoid receptor antagonist?. European Journal of Heart Failure, 2022, 24, 631-633.	7.1	0
60	Title is missing!. , 2020, 17, e1003419.		0
61	Title is missing!. , 2020, 17, e1003419.		0
62	Title is missing!. , 2020, 17, e1003419.		0
63	Title is missing!. , 2020, 17, e1003419.		0
64	Title is missing!. , 2020, 17, e1003419.		0
65	Title is missing!. , 2020, 15, e0236934.		0
66	Title is missing!. , 2020, 15, e0236934.		0
67	Title is missing!. , 2020, 15, e0236934.		0
68	Title is missing!. , 2020, 15, e0236934.		0